Oncotelic Therapeutics Inc
OTC:OTLC
Oncotelic Therapeutics Inc
Revenue
Oncotelic Therapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Oncotelic Therapeutics Inc
OTC:OTLC
|
Revenue
$70k
|
CAGR 3-Years
-66%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-7%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Oncotelic Therapeutics Inc's Revenue?
Revenue
70k
USD
Based on the financial report for Sep 30, 2023, Oncotelic Therapeutics Inc's Revenue amounts to 70k USD.
What is Oncotelic Therapeutics Inc's Revenue growth rate?
Revenue CAGR 10Y
-7%
The average annual Revenue growth rates for Oncotelic Therapeutics Inc have been -66% over the past three years , and -7% over the past ten years .